Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Zhou, Jiaolin ^a   Chang, Lianpeng ^b   Guan, Yanfang ^b   Yang, Ling ^b   Xia, Xuefeng ^c   Cui, Liqiang ^a   Yi, Xin ^b   Lin, Guole ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Geneplus Beijing ^*  (China)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; NON INVASIVE MEASUREMENT; OBSERVATIONAL STUDY; SOMATIC MUTATION; TUMOR VOLUME; VARIANT ALLELE FREQUENCY; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MUTATION; MUTATION RATE; PATHOLOGY;

AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE;

EID: 84979967880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159708     Document Type: Article

References (38)

1. Bohm B, Schwenk W, Hucke HP, Stock W. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Diseases of the colon and rectum. 1993; 36(3):280-6. Epub 1993/03/01. PMID: 8449134.
2. Scholefield JH, Steele RJ. Guidelines for follow up after resection of colorectal cancer. Gut. 2002; 51 Suppl 5:V3-5. Epub 2002/09/11. PMID: 12221030; PubMed Central PMCID: PMC1867738.
3. Umpleby HC, Fermor B, Symes MO, Williamson RC. Viability of exfoliated colorectal carcinoma cells. The British journal of surgery. 1984; 71(9):659-63. Epub 1984/09/01. PMID: 6478151.
4. Bast RC Jr., Ravdin P, Hayes DF, Bates S, Fritsche H Jr., Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19(6):1865-78. PMID: 11251019.
5. Kraus S, Nabiochtchikov I, Shapira S, Arber N. Recent advances in personalized colorectal cancer research. Cancer letters. 2014; 347(1):15-21. doi: 10.1016/j.canlet.2014.01.025 PMID: 24491406.
6. Liu Z, Zhang Y, Niu Y, Li K, Liu X, Chen H, et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PloS one. 2014; 9(8):e103910. doi: 10.1371/journal.pone.0103910 PMID: 25105762; PubMed Central PMCID: PMC4126674.
7. Sorbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(23):4466-7. doi: 10.1200/JCO.2003.99.200 PMID: 14645446.
8. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(45):16368-73. Epub 2005/11/01. doi: 10.1073/pnas.0507904102 PMID: 16258065; PubMed Central PMCID: PMC1283450.
9. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nature medicine. 2008; 14(9):985-90. Epub 2008/08/02. doi: 10.1038/nm.1789 PMID: 18670422; PubMed Central PMCID: PMC2820391.
10. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature medicine. 1996; 2(9):1035-7. Epub 1996/09/01. PMID: 8782464.
11. Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015. Epub 2015/02/07. doi: 10.1136/gutjnl-2014-308859 PMID: 25654990.
12. Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PloS one. 2016; 11(2):e0150197. Epub 2016/02/27. doi: 10.1371/journal.pone.0150197 PMID: 26918901; PubMed Central PMCID: PMC4769175.
13. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488(7413):660-4. Epub 2012/08/17. doi: 10.1038/nature11282 PMID: 22895193; PubMed Central PMCID: PMC3690621.
14. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science translational medicine. 2014; 6(224):224ra24. Epub 2014/02/21. doi: 10.1126/scitranslmed.3007094 PMID: 24553385; PubMed Central PMCID: PMC4017867.
15. Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, et al. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease. PloS one. 2015; 10(8):e0136407. doi: 10.1371/journal.pone.0136407 PMID: 26317216; PubMed Central PMCID: PMC4552879.
16. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 2015. Epub 2015/04/07. doi: 10.1016/S1470-2045(15)70106-3 PMID: 25842160.
17. Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer letters. 2016; 370(2):324-31. doi: 10.1016/j.canlet.2015.11.005 PMID: 26582655.
18. Nielsen R, Paul JS, Albrechtsen A, Song YS. Genotype and SNP calling from next-generation sequencing data. Nature reviews Genetics. 2011; 12(6):443-51. doi: 10.1038/nrg2986 PMID: 21587300; PubMed Central PMCID: PMC3593722.
19. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology. 2013; 31(3):213-9. doi: 10.1038/nbt.2514 PMID: 23396013; PubMed Central PMCID: PMC3833702.
20. Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics. 2012; 28(10):1307-13. doi: 10.1093/bioinformatics/bts146 PMID: 22474122; PubMed Central PMCID: PMC3348560.
21. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nature methods. 2009; 6(9):677-81. doi: 10.1038/nmeth.1363 PMID: 19668202; PubMed Central PMCID: PMC3661775.
22. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nature biotechnology. 2011; 29(1):24-6. doi: 10.1038/nbt.1754 PMID: 21221095; PubMed Central PMCID: PMC3346182.
23. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-9. doi: 10.1038/nature12634 PMID: 24132290; PubMed Central PMCID: PMC3927368.
24. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-8. doi: 10.1038/nature12213 PMID: 23770567; PubMed Central PMCID: PMC3919509.
25. Fearon ER. Molecular genetics of colorectal cancer. Annual review of pathology. 2011; 6:479-507. doi: 10.1146/annurev-pathol-011110-130235 PMID: 21090969.
26. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. doi: 10.1126/science.1145720 PMID: 17932254.
27. Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, et al. A Big Bang model of human colorectal tumor growth. Nature genetics. 2015; 47(3):209-16. doi: 10.1038/ng.3214 PMID: 25665006; PubMed Central PMCID: PMC4575589.
28. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England journal of medicine. 2013; 368(13):1199-209. Epub 2013/03/15. doi: 10.1056/NEJMoa1213261 PMID: 23484797.
29. Klevebring D, Neiman M, Sundling S, Eriksson L, Darai Ramqvist E, Celebioglu F, et al. Evaluation of exome sequencing to estimate tumor burden in plasma. PloS one. 2014; 9(8):e104417. doi: 10.1371/journal.pone.0104417 PMID: 25133800; PubMed Central PMCID: PMC4136786.
30. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine. 2015; 21(7):827. doi: 10.1038/nm0715-827b PMID: 26151329.
31. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating Tumor DNA as an Early Marker of Therapeutic Response in Patients with Metastatic Colorectal Cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015. Epub 2015/04/09. doi: 10.1093/annonc/mdv177 PMID: 25851626.
32. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. International journal of cancer. 2002; 100(5):542-8. doi: 10.1002/ijc.10526 PMID: 12124803.
33. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(36):14508-13. doi: 10.1073/pnas.1208715109 PMID: 22853953; PubMed Central PMCID: PMC3437896.
34. Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nature protocols. 2014; 9(11):2586-606. doi: 10.1038/nprot.2014.170 PMID: 25299156; PubMed Central PMCID: PMC4271547.
35. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine. 2014; 20(5):548-54. doi: 10.1038/nm.3519 PMID: 24705333; PubMed Central PMCID: PMC4016134.
36. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. The American journal of gastroenterology. 2005; 100(6):1393-403. doi: 10.1111/j.1572-0241.2005.41427.x PMID: 15929776.
37. Tao S, Hundt S, Haug U, Brenner H. Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. The American journal of gastroenterology. 2011; 106(2):242-53. doi: 10.1038/ajg.2010.393 PMID: 20959816.
38. Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013; 62(11):1523-8. doi: 10.1136/gutjnl-2013-305300 PMID: 23903238.